INTRODUCTION: Diagnosis of the limb-girdle muscular dystrophies (LGMDs) has been facilitated by the use of immunofluorescence microscopy, Western blot analysis, and rapid genetic testing. METHODS: We identified 7 patients with LGMD2B or Miyoshi myopathy (MM) phenotypes and performed detailed history, physical examination, and mutation analyses of genomic DNA. RESULTS: Ten disease-causing variants of the dysferlin gene (DYSF) were detected, 4 of which were novel and predicted to be pathogenic (IVS33+9G>T, c.1343T>C, c.4747T>G, and c.5066dupC). Two of these mutations (c.1343T>C and IVS33+9G>T) were associated with a reduction in sarcolemmal dysferlin expression, despite increased total mRNA and protein in mixed muscle homogenates, due to a pathological retention of the mutated polypeptide in the cytoplasm. CONCLUSIONS: Considering that protein-based assays may yield false negative test results and that dysferlin aggregation may be present in other LGMDs, mutational screening is necessary for specific diagnosis in primary dysferlinopathy patients exhibiting this phenotype.
INTRODUCTION: Diagnosis of the limb-girdle muscular dystrophies (LGMDs) has been facilitated by the use of immunofluorescence microscopy, Western blot analysis, and rapid genetic testing. METHODS: We identified 7 patients with LGMD2B or Miyoshi myopathy (MM) phenotypes and performed detailed history, physical examination, and mutation analyses of genomic DNA. RESULTS: Ten disease-causing variants of the dysferlin gene (DYSF) were detected, 4 of which were novel and predicted to be pathogenic (IVS33+9G>T, c.1343T>C, c.4747T>G, and c.5066dupC). Two of these mutations (c.1343T>C and IVS33+9G>T) were associated with a reduction in sarcolemmal dysferlin expression, despite increased total mRNA and protein in mixed muscle homogenates, due to a pathological retention of the mutated polypeptide in the cytoplasm. CONCLUSIONS: Considering that protein-based assays may yield false negative test results and that dysferlin aggregation may be present in other LGMDs, mutational screening is necessary for specific diagnosis in primary dysferlinopathypatients exhibiting this phenotype.
Authors: Elizabeth Harris; Catherine L Bladen; Anna Mayhew; Meredith James; Karen Bettinson; Ursula Moore; Fiona E Smith; Laura Rufibach; Avital Cnaan; Diana X Bharucha-Goebel; Andrew M Blamire; Elena Bravver; Pierre G Carlier; John W Day; Jordi Díaz-Manera; Michelle Eagle; Ulrike Grieben; Matthew Harms; Kristi J Jones; Hanns Lochmüller; Jerry R Mendell; Madoka Mori-Yoshimura; Carmen Paradas; Elena Pegoraro; Alan Pestronk; Emmanuelle Salort-Campana; Olivia Schreiber-Katz; Claudio Semplicini; Simone Spuler; Tanya Stojkovic; Volker Straub; Shin'ich Takeda; Carolina Tesi Rocha; M C Walter; Kate Bushby Journal: Neurol Genet Date: 2016-08-04
Authors: Muhammad I Ullah; Arsalan Ahmad; Milena Zarkovic; Syed S Shah; Abdul Nasir; Saqib Mahmood; Wasim Ahmad; Christian A Hubner; Muhammad J Hassan Journal: Saudi Med J Date: 2017-12 Impact factor: 1.484
Authors: Elizabeth Harris; Ana Topf; Rita Barresi; Judith Hudson; Helen Powell; James Tellez; Debbie Hicks; Anna Porter; Marta Bertoli; Teresinha Evangelista; Chiara Marini-Betollo; Ólafur Magnússon; Monkol Lek; Daniel MacArthur; Kate Bushby; Hanns Lochmüller; Volker Straub Journal: Orphanet J Rare Dis Date: 2017-09-06 Impact factor: 4.123
Authors: Mats I Nilsson; Lauren G Macneil; Yu Kitaoka; Fatimah Alqarni; Rahul Suri; Mahmood Akhtar; Maria E Haikalis; Pavneet Dhaliwal; Munim Saeed; Mark A Tarnopolsky Journal: PLoS One Date: 2014-07-31 Impact factor: 3.240